Aspirin not a substitute for colorectal cancer screening

November 05, 2001

PHILADELPHIA -- Aspirin is not a cost-effective preventive measure or substitute for colorectal cancer screening tests, a new study finds. Some studies have suggested that aspirin and other non-steroidal anti-inflammatory drugs might reduce risk for colorectal cancer. The study is published in the November 6, 2001, issue of Annals of Internal Medicine.

Researchers at the University of California, San Francisco (UCSF) and the University of Michigan developed a computer simulation based on the natural history of colorectal cancer, performance of three recommended screening tests, and an assumption that aspirin could reduce colorectal cancer death by 30 percent. In various computations of the data, using aspirin actually increased costs and resulted in loss of life-years.

"While aspirin may be of some benefit in colorectal cancer prevention, it should not replace known screening methods," said Uri Ladabaum, MD, MS, assistant professor of gastroenterology at UCSF and lead author of the study.

"In addition, in terms of cost and benefits, it does not make sense for patients already getting regular screening to take aspirin to prevent colorectal cancer. Recommended screening is highly cost-effective and remains so, even in patients already taking aspirin for other reasons like arthritis or prevention of heart disease," Ladabaum said.

"Available screening tests for colorectal cancer are highly effective in detecting disease at a curable stage. Unfortunately, less than half of Americans undergo these life-saving screening examinations as recommended by medical societies," said A. Mark Fendrick, MD, associate professor of medicine at the University of Michigan and the study's senior investigator. "Improving screening rates among adults -- especially those at increased risk for colorectal cancer -- should be the primary goal of a national agenda to prevent colorectal cancer death," Fendrick said.

A video news release on this article will be available on Monday, Nov. 5.
Annals of Internal Medicine, a peer-reviewed medical journal, is published in Philadelphia by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM). ACP-ASIM is the second-largest physician group in the United States, with 115,000 members providing quality health care to adult patients.


Copies of the article, "Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer: a Cost-Effectiveness Analysis," can be obtained by calling the ACP-ASIM Communications Dept. at 1-800-523-1546, ext. 2656.

Dr. Ladabaum can be reached by calling Maureen McInaney at 415-476-2557.

Dr. Fendrick can be reached by calling Susan Quigley at 734-647-9688. A video news release on this article can be accessed by wire on November 5, embargoed for release until 5 pm ET.

9:00 AM - 9:30 AM, ET
Telstar 6, Transponder 11, C-Band (HOLD)
Downlink Freq: 3920 (V)

2:00 PM - 2:30 PM, ET
(14:00 PM - 14:30 PM, ET)
Telstar 6, Transponder 11, C-Band (HOLD)
Downlink Freq: 3920 (V)

American College of Physicians

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to